Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Pharvaris (Nasdaq: PHVS) will present new clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the EAACI Annual Congress 2026 in Istanbul from June 12-15, 2026.

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS) will present new clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the EAACI Annual Congress 2026 in Istanbul from June 12-15, 2026.

According to Pharvaris, one oral presentation and seven flash talk/poster sessions will cover Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 results in hereditary angioedema, cardiovascular safety, biomarker development, long-term prophylaxis, and patient-reported outcomes. Slides and posters will be posted on its investor website at the time of each presentation.

Argus May 29 session

+1.00% close to close Open Argus

Details

News Market Reaction – PHVS

On May 29, the day this news came out, PHVS closed 1.00% above the previous close.

Data tracked by StockTitan Argus for the May 29 session.

Key Figures

Cash & equivalents: €247 million Underwritten offering: $132.3 million Year-end cash: €292 million +5 more

Cash & equivalents

€247 million

On March 31, 2026, before $132.3M offering

Underwritten offering

$132.3 million

Ordinary share offering closed May 11, 2026

Year-end cash

€292 million

Cash at December 31, 2025

Onset of relief

1.28 hours

RAPIDe-3 median time to symptom relief vs >12h placebo

End of Progression

17.47 minutes

RAPIDe-3 End of Progression vs 228.67 minutes placebo

Symptom resolution

11.95 hours

RAPIDe-3 median time to complete symptom resolution

Single-capsule attacks

83.0%

RAPIDe-3 attacks treated with one deucrictibant capsule

No rescue medication

93.2%

RAPIDe-3 attacks managed without rescue therapy

Previous Clinical trial Reports

5 past events · Latest: Feb 10

Same Type 5 events

1. Feb 10

   Conference data preview

   24h Move

   +1.7%

   Announced six deucrictibant abstracts at AAAAI 2026, including pivotal Phase 3 data.

2. Dec 03

   Pivotal topline data

   24h Move

   +21.8%

   Reported RAPIDe-3 Phase 3 success with strong efficacy and tolerability for on-demand HAE.

3. Jul 10

   Timeline update

   24h Move

   +7.2%

   Pushed RAPIDe-3 topline timing to Q4 2025 while reiterating NDA plans for 1H 2026.

4. Jun 27

   Summit presentations

   24h Move

   -5.0%

   Planned multiple HAE trial posters showing long-term safety, efficacy and QoL data.

5. Jun 02

   Data at workshop

   24h Move

   -0.7%

   Presented promising prophylactic and on-demand deucrictibant results and a novel biomarker assay.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bradykinin b2 receptor antagonists, hereditary angioedema, acquired angioedema due to c1 inhibitor deficiency, phase 3, +4 more

8 terms

bradykinin b2 receptor antagonists medical

"developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs"

Bradykinin B2 receptor antagonists are drugs that block a specific cell receptor which responds to bradykinin, a natural molecule that causes blood vessels to leak, swell and send pain signals; blocking that receptor can reduce swelling, pain and inflammation. For investors, these drugs matter because successful candidates can address acute or chronic conditions with high unmet need, and their clinical trial results, safety profile and regulatory approvals strongly influence a company’s market value—think of the drug as putting a cap on a leaking pipe to stop costly damage.

hereditary angioedema medical

"bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

acquired angioedema due to c1 inhibitor deficiency medical

"and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH)"

A rare disorder where the body lacks or destroys a protein called C1 inhibitor, causing sudden, painful swelling in tissues such as the face, throat or abdomen; think of it as a faulty brake system that lets swelling responses run unchecked. For investors, it matters because its rarity and severity drive demand for specialized diagnostics, treatments and ongoing clinical development, affecting market opportunities, regulatory risk and potential healthcare spending.

phase 3 medical

"End of Progression Results in the Phase 3 RAPIDe-3 Trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

open-label extension medical

"Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

prophylaxis medical

"oral Deucrictibant for Prophylaxis in Hereditary Angioedema"

Prophylaxis is a medical prevention strategy — a drug, vaccine, device, or procedure given to stop a disease or condition before it starts. For investors, prophylactic products matter because they can create steady, large markets and reduce long‑term healthcare costs; regulatory approval or broader adoption can change demand forecasts much like a new safety feature that becomes standard across an entire industry.

health-related quality of life medical

"Improved Disease Control and Health-Related Quality of Life in Participants"

A measure of how a person’s health status affects their ability to live, work and enjoy life, covering physical comfort, mental well‑being and social participation, usually captured by patient questionnaires and numeric scores. Investors care because improvements in these scores can drive regulatory approval, insurance coverage, patient demand and pricing, much like customer satisfaction ratings predict whether a product will sell and generate revenue.

bradykinin-mediated medical

"Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema"

A process driven by the peptide bradykinin, which acts like a chemical signal that widens blood vessels, makes vessel walls leakier and triggers pain and swelling. When a condition or drug effect is described as bradykinin-mediated, it means bradykinin is the main cause of symptoms or therapeutic action, similar to a faucet turning up flow and pressure in a plumbing system. Investors care because treatments that block or enhance this pathway can change disease outcomes, side-effect profiles and market value for related drugs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey.

Details of the presentations are as follows:

• Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial
  Presenter: Mauro Cancian, M.D., Ph.D.
  Format: Oral Presentation
  Date, time: Friday, June 12, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)

• Title: Clinical Cardiovascular Safety Assessment of Oral Deucrictibant
  Presenter: Anne Lesage, Ph.D.
  Format: Poster Presentation
  Date, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

• Title: A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema
  Presenter: Evangelia Pardali, Ph.D.
  Format: Poster Presentation
  Date, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

• Title: Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule
  Presenter: Anne Lesage, Ph.D.
  Format: Poster Presentation
  Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

• Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
  Presenter: Philip Li, M.D., FRCP
  Format: Poster Presentation
  Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

• Title: RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
  Presenter: Anna Valerieva, M.D., Ph.D.
  Format: Poster Presentation
  Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)

• Title: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema
  Presenter: Markus Magerl, M.D.
  Format: Flash Talk
  Date, time: Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)

• Title: CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema
  Presenter: Markus Magerl, M.D.
  Format: Flash Talk
  Date, time: Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Vice President, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What clinical data will Pharvaris (PHVS) present at EAACI 2026 on deucrictibant?

Pharvaris will present multiple clinical datasets on oral deucrictibant in hereditary angioedema. According to Pharvaris, these include Phase 3 RAPIDe-3 on-demand treatment results, Phase 2 CHAPTER-1 long-term prophylaxis data, cardiovascular safety analyses, biomarker assay validation, and patient-reported outcomes.

When and where is Pharvaris (PHVS) presenting at the EAACI 2026 congress?

Pharvaris is presenting at the EAACI Annual Congress 2026 from June 12-15 in Istanbul, Turkey. According to Pharvaris, sessions run June 12 and 13, 2026, across oral, poster, and flash talk formats covering deucrictibant clinical programs in hereditary angioedema.

What is the RAPIDe-3 Phase 3 trial of deucrictibant that Pharvaris (PHVS) will discuss?

RAPIDe-3 is a Phase 3 trial evaluating oral deucrictibant immediate-release capsules for on-demand treatment of hereditary angioedema attacks. According to Pharvaris, EAACI 2026 presentations include end-of-progression results, overall trial outcomes, and qualitative patient voice insights from the study population.

What long-term prophylaxis data from the CHAPTER-1 study will Pharvaris (PHVS) share at EAACI 2026?

Pharvaris will share Phase 2 CHAPTER-1 open-label extension data on long-term prophylactic treatment with oral deucrictibant. According to Pharvaris, flash talks will address extended safety, efficacy for hereditary angioedema prophylaxis, disease control, and health-related quality-of-life outcomes in study participants.

How can investors access Pharvaris (PHVS) EAACI 2026 presentation materials?

Investors can access Pharvaris’ EAACI 2026 posters and slide decks on its investor relations website. According to Pharvaris, materials will be posted in the Investors section at the start of each scheduled presentation, aligning with congress session times in Istanbul.

Which aspects of deucrictibant safety and biomarkers will Pharvaris (PHVS) highlight at EAACI 2026?

Pharvaris will present cardiovascular safety assessments and kinin biomarker assay data related to oral deucrictibant. According to Pharvaris, posters will cover clinical cardiovascular safety evaluation and a clinically validated kinin biomarker assay differentiating bradykinin-mediated from mast cell-mediated angioedema.